Centre for Advanced Medical Products
| Reference number | |
| Coordinator | Umeå universitet - Institutionen för integrativ medicinsk biologi |
| Funding from Vinnova | SEK 52 000 000 |
| Project duration | January 2018 - December 2024 |
| Status | Ongoing |
Purpose and goal
Advanced therapies based on genes, cells or tissues (ATMP), have a great potential to generate completely new ways to treat patients; even to stop, reverse or cure diseases and injuries. Centre for Advanced Medical Products (CAMP) focuses on the science, technology and infrastructure required to translate ATMP from laboratory to clinical practice. The Centre also addresses systems and organisational challenges which have been identified as hurdles for development of the ATMP field in Sweden.
Expected effects and result
Integration of pre-clinical, clinical, engineering and other scientific areas, with commercialisation competencies will accelerate research translation, enabling new patient treatments, and generate industrial growth. The project will optimise collaboration between ATMP infrastructures and activities in academia/healthcare and commercial pre-clinical and clinical R&D. This will facilitate further development and commercialisation of ATMP and thus increase Sweden’s competitiveness in this field.
Planned approach and implementation
Research and innovation projects focusing on critical technological aspects of development and manufacturing of ATMP will run in parallel with Cross Cutting Priority challenges identified as important barriers or enablers for the development of the field. This combined approach will connect academic, clinical and industrial research and development in Sweden. Within the period 2018-2023, CAMP will be established as an internationally recognized centre for research and development of ATMP.